Multiple System AtrophyNCT07805967
Multi-Center Study of Natural History in Atypical Parkinsonian Syndromes (MAPS-NH)
An observational study of Multiple System Atrophy and Dementia With Lewy Bodies (DLB), run by Second Affiliated Hospital of Soochow University at 20 sites in China.
Trial summary
This goal of this observational study is to clarify the variations in the natural course of atypical parkinsonian syndromes (APS, including MSA, DLB, PSP, and CBD), such as the progression rate of motor and non-motor symptoms and characteristic imaging evolution patterns. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Multiple System Atrophy, Dementia With Lewy Bodies (DLB), Progressive Supranuclear Palsy (PSP)
- What is being tested?
- We did not apply any interventions; only observational research was conducted.
- How many people
- 500 participants
- Where
- 20 sitesChina
- Study dates
- 12 Nov 2025to 31 Aug 2030
- How long will I take part?
- 3 Years
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients diagnosed with multiple system atrophy (MSA) , dementia with Lewy bodies (DLB) , progressive supranuclear palsy (PSP) , or corticobasal degeneration (CBD) according to Chinese/international consensus diagnostic criteria . Follow-up period : 3 years , with clinical phenotypes and/or biomarkers assessed every 6 months .
Who may be able to join
- MSA : Meets the "probable MSA" criteria in the 2022 Chinese expert consensus on MSA diagnosis (MSA-P or MSA-C subtype); disease duration ≤3 years (from onset of first motor symptoms) .
- DLB : Meets "probable DLB" criteria per the 2017 McKeith diagnostic criteria; MMSE ≥18 (to exclude severe dementia confounding assessment) .
- PSP : Meets "probable PSP-Richardson syndrome" criteria per the 2017 PSP diagnostic standards; vertical gaze palsy or postural instability with duration ≤2 years .
- CBD : Meets "probable CBD" criteria per the 2019 Chinese expert consensus on corticobasal degeneration diagnosis and treatment; asymmetric cortical symptoms (apraxia/dystonia/alien limb).
Who cannot join
- Parkinson's disease , spinocerebellar ataxia (SCA) and other secondary autonomic failure .
- Vascular parkinsonism , Parkinsonism caused by stroke , tumor , or immune-mediated encephalitis .
Trial locations and contacts
20 sites in 1 country. Contact the study team or a site near you to ask about taking part.
20 sites in 1 country
China20 sites, 20 recruiting
- Recruiting
Changshu Hospital Affiliated to Nanjing University of Chinese Medicine
Changshu, Jiangsu, 215500
Juping Chen, +8618662128292, chenjuping623@sina.com
- Not yet recruiting
Deyang People's Hospital
Deyang
Ping Zhang, +8615883850268
- Not yet recruiting
The second People's Hospital of Huai'an
Huai'an, Jiangsu, 223001
Xiangyang Cao, +8613952338186, 13952338186@126.com
- Not yet recruiting
Changxing people' s hospital
Huzhou
Donghui Li, +8615067223301
- Not yet recruiting
Jiaxing Second Hospital
Jiaxing, Zhejiang, 314000
Yanping Wang, +8613486331646
- Not yet recruiting
The First People's Hospial of Kunshan
Kunshan, Jiangsu, 215300
Qing, Tang, +8618862390859
- Not yet recruiting
Mianyang 404 Hospital
Mianyang, Sichuan, 621000
Zongqin Li, +8618009080187, 527217803@qq.com
- Not yet recruiting
Jiangsu Province Official Hospital
Nanjing, Jiangsu, 210000
Huifen Zheng, +8613357818755, staff765@yxph.com
- Not yet recruiting
The Second Affiliated Hospital of Nantong University
Nantong, Jiangsu, 226000
Jia Li, +8613813605009
- Not yet recruiting
Affiliated Hospital of Nantong University
Nantong
Xiaosu Gu, 13962998759
- Recruiting
Jiangsu Province (Suqian) Hospital
Suqian, Jiangsu, 223800
Dan Li, +8613776468080
- Recruiting
The Forth Affiliated Hospital of Soochow University
Suzhou, Jiangsu, 215000
Yali Wang, +8613771862186, yjyali@sina.com
- Recruiting
The Second Affiliated Hospital of Soochow University
Suzhou, Jiangsu, 215000
Jinru Zhang, +8615850210657, zhangjinruruby@126.com
Chunfeng Liu
- Not yet recruiting
The Second Affiliated Hospital of Xuzhou Medical University
Xuzhou, Jiangsu, 221000
Zhining Li, +8618752150083, zningdoctor@126.com
- Not yet recruiting
The Affiliated Hospital of Xuzhou Medical University
Xuzhou
Liguo Dong, +8618795425932, dongliguo@xzhmu.edu.cn
- Recruiting
Yancheng Third People's Hospital
Yancheng, Jiangsu, 224000
Haihua Sun, +8615295370576
- Not yet recruiting
Affiliated Hospital of Yangzhou University
Yangzhou, Jiangsu, 225000
Jiangbing Liu, +8613401291476, 34605558@qq.com
- Not yet recruiting
Yantai Yuhuangding Hospital
Yantai, Shandong, 264000
Chao Ren, +8618563802311, renchaotg@126.com
- Not yet recruiting
Zhangjiagang TCM Hospital Affiliated to Nanjing University of Chinese Medicine/Zhangjiagang Traditional Chinese Medicine Hospital
Zhangjiagang, Jiangsu, 215600
Yaming Sun, +8613773241027, sunyaming2001@126.com
- Recruiting
The Forth People's Hospital of Zhenjiang
Zhenjiang, Jiangsu, 212000
Jinjun Qian, +8615358595730
About this study
This goal of this observational study is to clarify the variations in the natural course of atypical parkinsonian syndromes (APS, including MSA, DLB, PSP, and CBD), such as the progression rate of motor and non-motor symptoms and characteristic imaging evolution patterns. Establish a comprehensive assessment framework for APS, and develop clinical and biological databases to identify biomarkers with early predictive value.
- Conditions
- Multiple System Atrophy, Dementia With Lewy Bodies (DLB), Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD)
- Being tested
- We did not apply any interventions; only observational research was conducted.
- Medical subject headings
- Multiple System Atrophy, Lewy Body Disease, Supranuclear Palsy, Progressive, Corticobasal Degeneration
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
We did not apply any interventions; only observational research was conducted.Other
We did not apply any interventions; only observational research was conducted.
| Study group | Role | What they receive |
|---|---|---|
| Atypical parkinsonian syndromes | Not described Receives: Other: We did not apply any interventions; only observational research was conducted. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Natural disease progression of various atypical parkinsonian syndromes
To observe the differences in the natural disease progression of various atypical parkinsonian syndromes (APS, including MSA, DLB, PSP, and CBD), such as the progression rates of motor and non-motor symptoms and the patterns of imaging evolution. The preliminary study design involves a follow-up period of 3 years, with assessments of clinical phenotypes and/or biomarker changes every 6 months.
Measured: up to 36 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Sep 2026
- Study start12 Nov 2025
- Primary completion31 Aug 2030 (estimated)
- Study completion31 Aug 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Multiple System AtrophyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 500 participants (estimated)
- Target duration
- 3 Years
Sponsor and investigators
- Lead sponsor
- Second Affiliated Hospital of Soochow University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Chunfeng Liu, Study chair, Second Affiliated Hospital of Soochow University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07805967
- Sponsor's protocol ID
- JD-LK2025118-I01
- Status last verified
- Sep 2026
- First submitted
- 20 Nov 2025
- Last updated
- 8 Sep 2026
- Results posted
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 8 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Multi-Center Study of Natural History in Atypical Parkinsonian Syndromes (MAPS-NH)
- ClinicalTrials.gov ID
- NCT07805967
- Acronym / sponsor ID
- JD-LK2025118-I01
- Conditions
- Multiple System Atrophy, Dementia With Lewy Bodies (DLB), Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD)
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 500 participants (estimated)
- Lead sponsor
- Second Affiliated Hospital of Soochow UniversityUniversity, hospital or other
- Study start
- 12 Nov 2025 (actual)
- Primary completion
- 31 Aug 2030 (estimated)
- Study completion
- 31 Aug 2030 (estimated)
- First posted
- 8 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This goal of this observational study is to clarify the variations in the natural course of atypical parkinsonian syndromes (APS, including MSA, DLB, PSP, and CBD), such as the progression rate of motor and non-motor symptoms and characteristic imaging evolution patterns. Establish a comprehensive assessment framework for APS, and develop clinical and biological databases to identify biomarkers with early predictive value.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 3 Years
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Atypical parkinsonian syndromes | – | Other: We did not apply any interventions; only observational research was conducted. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients diagnosed with multiple system atrophy (MSA) , dementia with Lewy bodies (DLB) , progressive supranuclear palsy (PSP) , or corticobasal degeneration (CBD) according to Chinese/international consensus diagnostic criteria . Follow-up period : 3 years , with clinical phenotypes and/or biomarkers assessed every 6 months .
Key inclusion criteria (4 listed)
- MSA : Meets the "probable MSA" criteria in the 2022 Chinese expert consensus on MSA diagnosis (MSA-P or MSA-C subtype); disease duration ≤3 years (from onset of first motor symptoms) .
- DLB : Meets "probable DLB" criteria per the 2017 McKeith diagnostic criteria; MMSE ≥18 (to exclude severe dementia confounding assessment) .
- PSP : Meets "probable PSP-Richardson syndrome" criteria per the 2017 PSP diagnostic standards; vertical gaze palsy or postural instability with duration ≤2 years .
- CBD : Meets "probable CBD" criteria per the 2019 Chinese expert consensus on corticobasal degeneration diagnosis and treatment; asymmetric cortical symptoms (apraxia/dystonia/alien limb).
Key exclusion criteria (2 listed)
- Parkinson's disease , spinocerebellar ataxia (SCA) and other secondary autonomic failure .
- Vascular parkinsonism , Parkinsonism caused by stroke , tumor , or immune-mediated encephalitis .
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| We did not apply any interventions; only observational research was conducted.We did not apply any interventions; only observational research was conducted. | Other | Atypical parkinsonian syndromes |
Primary outcome
Natural disease progression of various atypical parkinsonian syndromes
Time frame: up to 36 months
To observe the differences in the natural disease progression of various atypical parkinsonian syndromes (APS, including MSA, DLB, PSP, and CBD), such as the progression rates of motor and non-motor symptoms and the patterns of imaging evolution. The preliminary study design involves a follow-up period of 3 years, with assessments of clinical phenotypes and/or biomarker changes every 6 months.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Sep 2026.
- Individual participant dataSharing planned: No
Related trials for Multiple System Atrophy
Enrolling by invitationObservational study
Early Molecular Biomarkers for Differentiating Parkinsonian Syndromes
PARKINSON DISEASE (Disorder), Atypical Parkinsonism
Active, not recruitingPhase 2
A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy
Multiple System Atrophy
RecruitingPhase 1/2
Tributyrin for Progressive Supranuclear Palsy (PSP): Virtual Trial
Parkinson Disease, Multiple System Atrophy
RecruitingObservational study
A Study of Risdiplam in Participants With Type I and Type II Spinal Muscle Atrophy (SMA)
Spinal Muscle Atrophy
RecruitingObservational study
Comparison of Individuals With Primary Ciliary Dyskinesia and Healthy Controls
Primary Ciliary Dyskinesia (PCD)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Chunfeng Liu study chair
Second Affiliated Hospital of Soochow University
20 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Multiple System Atrophy and Dementia With Lewy Bodies (DLB), run by Second Affiliated Hospital of Soochow University at 20 sites in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 8 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 20 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Jinru Zhang, PhD. MD. (+8615850210657, zhangjinruruby@126.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Natural disease progression of various atypical parkinsonian syndromes (time frame: up to 36 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Sep 2026.